全文获取类型
收费全文 | 8391篇 |
免费 | 328篇 |
国内免费 | 89篇 |
专业分类
耳鼻咽喉 | 41篇 |
儿科学 | 99篇 |
妇产科学 | 112篇 |
基础医学 | 1234篇 |
口腔科学 | 130篇 |
临床医学 | 384篇 |
内科学 | 2286篇 |
皮肤病学 | 154篇 |
神经病学 | 813篇 |
特种医学 | 323篇 |
外科学 | 1557篇 |
综合类 | 26篇 |
预防医学 | 217篇 |
眼科学 | 60篇 |
药学 | 480篇 |
中国医学 | 34篇 |
肿瘤学 | 858篇 |
出版年
2023年 | 35篇 |
2022年 | 54篇 |
2021年 | 112篇 |
2020年 | 70篇 |
2019年 | 86篇 |
2018年 | 136篇 |
2017年 | 102篇 |
2016年 | 119篇 |
2015年 | 141篇 |
2014年 | 197篇 |
2013年 | 250篇 |
2012年 | 373篇 |
2011年 | 485篇 |
2010年 | 283篇 |
2009年 | 270篇 |
2008年 | 480篇 |
2007年 | 488篇 |
2006年 | 505篇 |
2005年 | 540篇 |
2004年 | 548篇 |
2003年 | 606篇 |
2002年 | 627篇 |
2001年 | 135篇 |
2000年 | 116篇 |
1999年 | 154篇 |
1998年 | 183篇 |
1997年 | 167篇 |
1996年 | 132篇 |
1995年 | 115篇 |
1994年 | 136篇 |
1993年 | 111篇 |
1992年 | 89篇 |
1991年 | 74篇 |
1990年 | 81篇 |
1989年 | 73篇 |
1988年 | 79篇 |
1987年 | 54篇 |
1986年 | 45篇 |
1985年 | 38篇 |
1984年 | 43篇 |
1983年 | 47篇 |
1982年 | 53篇 |
1981年 | 47篇 |
1980年 | 45篇 |
1979年 | 33篇 |
1978年 | 36篇 |
1977年 | 18篇 |
1976年 | 20篇 |
1975年 | 21篇 |
1966年 | 19篇 |
排序方式: 共有8808条查询结果,搜索用时 421 毫秒
11.
K Nakayama Y Nemoto Y Inoue T Mochizuki S B Soares Jr K Ohata J Katsuyama Y Onoyama K Wakasa 《AJNR. American journal of neuroradiology》1997,18(2):331
Cranial malignant fibrous histiocytomas are rare tumors. Most are hypervascular, destructive masses that are similar to other malignant lesions and to malignant fibrous histiocytomas found elsewhere in the body. We describe a myxoid malignant fibrous histiocytoma of the temporal bone, possibly of dural origin, with features that more closely resembled a meningioma at CT, MR imaging, and angiography. 相似文献
12.
Tetsuo Nagatani Megumi Miyazawa Toshiko Matsuzaki Gaijiro Iemoto Shu-taku Kim Naoko Baba Kanata Miyakawa Hideaki Miyamoto Hiroshi Nakajima Yoshio Hirai 《The Journal of dermatology》1993,20(10):623-629
A 45-year-old man was referred to our department in March of 1989. Physical examination showed erythroderma, palmo-plantar hyperkeratosis, generalized lymphadenopathy, hepatosplenomegaly, and leukemic manifestation. The lymphocyte count in the peripheral blood before treatment was 1.7 × 104 cells/mm3. Atypical lymphocytes such as flower cells and lobulated cells were seen in the peripheral blood. A sample excised from a lymph node showed immunoblastic, pleomorphic T cells by a modified classification scheme of the Working Formulation. A high level of serum LDH was detected (2.1 times the upper normal limit). Anti HTLV-1 antibody was also detected in the serum. The atypical lymphocytes were positive for CD3, CD4, CD5, CD7 and HLA-DR, and negative for CD8. Thus, the clinical, pathologic and immunologic features were those of typical acute-type ATL. The patient was treated with VEPA-M for three months starting in March of 1989. Because of poor response, the patient was then treated with MACOP-B, M-FEPA, and VEPP-B for about one year from June of 1989 and has been free of disease up to the time of writing, March of 1993. 相似文献
13.
Charles R. Ashby Yoshio Minabe Alon Toor Lyle D. Fishkin Martin I. Granoff Rex Y. Wang 《Drug development research》1994,31(3):228-236
This study examined the effect of acute and chronic administration of the selective 5-HT3 receptor antagonist BRL 46470A, an analog of granisetron, on the number of spontaneously active dopamine (DA) cells in the substantia nigra pars compacta (A9 or SNC) and the ventral tegmental area (A10 or VTA) in the rat. In the A10 area, the acute administration of BRL 46470A decreased the number of spontaneously active DA cells at a dose of 0.1 mg/kg (0.28 μmol/kg) ip, yet increased the number of spontaneously active DA cells at a dose of 0.3 mg/kg (0.84 μmol/kg). The chronic administration (21 days) of BRL 46470A appeared to produce a multiphasic dose-response curve. Thus, the chronic treatment with BRL 46470A increased the number of spontaneously active A10 DA cells at 0.03 (0.084 μmol) and 0.3 mg/kg, but decreased the number of spontaneously active A10 DA cells at a dose of 0.1 mg/kg. In contrast, BRL 46470A did not decrease the number of spontaneously active A9 DA cells after either acute or chronic administration (0.01-0.3 mg/kg). However, BRL 46470A did increase the number of spontaneously active A9 DA cells at acute and chronic doses similar to those that were effective in A10. The iv administration of (+)-apomorphine (APO) not only failed to reverse the decrease produced by chronic administration of BRL 46470A at 0.1 mg/kg, but further decreased the number of spontaneously active A10 DA cells. Similar to the results obtained with granisetron, the pretreatment of naive rats with either 0.01 or 0.1 mg/kg iv of BRL 46470A significantly potentiated (2-fold) the suppressant action of APO on the basal firing rate of A10, but not A9 DA cells. Overall, our results indicate that similar to granisetron, chronic BRL 46470A at 0.1 mg/kg selectively decreases the number of spontaneously active A10 DA cells, via a mechanism not related to depolarization inactivation. Presently, it is not clear what factors may contribute to the multiphasic dose-response curve of BRL 46470A. © 1994 Wiley-Liss, Inc. 相似文献
14.
15.
Seijiro Yoshida Yoshio Nitta Katsuhiko Oda 《The Japanese Journal of Thoracic and Cardiovascular Surgery》2005,53(4):230-233
A 65-year-old patient with ischemic heart disease and severe diabetes mellitus underwent minimally invasive direct coronary
artery bypass grafting under general combined with epidural anesthesia. Paraplegia developed after surgery and the diagnosis
of anterior spinal artery syndrome was made based on the patient s neurological condition and magnetic resonance imaging findings.
Paraplegia following epidural anesthesia is a rare but recognized complication and this complication should be taken into
account, especially in patients at risk, when considering epidural analgesia techniques in the minimally invasive cardiac
surgery. 相似文献
16.
Joji Ishikawa Satoshi Hoshide Seiichi Shibasaki Yoshio Matsui Tomoyuki Kabutoya Kazuo Eguchi Shizukiyo Ishikawa Thomas G Pickering Kazuyuki Shimada Kazuomi Kario 《Hypertension research》2006,29(3):153-159
Morning blood pressure is reported to be more closely related to hypertensive organ damages such as left ventricular mass index, microalbuminuria and silent cerebral infarcts, than blood pressure at other times of the day. Morning blood pressure may play an important role in the pathogenesis of hypertensive target organ damage. Increased sympathetic nerve activity is reported to be one of the mechanisms of morning hypertension; however, there are no available data that show whether strict home blood pressure control, especially in the morning period, can reduce target organ damage. The Japan Morning Surge-1 (JMS-1) study includes hypertensive outpatients with elevated morning systolic blood pressure (>or=135 mmHg) as assessed by self-measured blood pressure monitoring at home. All enrolled patients are under stable antihypertensive medication status. Exclusion criteria are arrhythmia, chronic inflammatory disease, and taking alpha-blockers or beta-blockers. The target number of patients to be enrolled in the JMS-1 study is 600, and the aim is to evaluate differences in the markers of hypertensive target organ damage, such as brain natriuretic peptide and the urinary albumin excretion/creatinine ratio. All of the patients are randomized to an experimental group or a control group, with randomization to be carried out by telephone interviews with the patients' physicians. In the experimental group, patients begin taking additional antihypertensive medication just before going to bed. This consists of doxazosin 1 mg/day, which then is increased to 2 mg/day and 4 mg/day, with a beta-blocker added after a 1-month interval until the morning systolic blood pressure is controlled to less than 135 mmHg. Patients in the control group continue the treatment they are receiving at the enrollment for 6 months. Blood pressure levels, adverse effects, and hypertensive target organ damage before and after the study are evaluated. In the JMS-1 study, we will evaluate whether strict morning blood pressure control by sympathetic nervous system blockade using an alpha-blocker, doxazosin, and with the addition of a beta-blocker if needed, can reduce hypertensive target organ damage. 相似文献
17.
Jong Il Kim Takeshi Tsujino Yoshio Fujioka Komei Saito Mitsuhiro Yokoyama 《Hypertension research》2003,26(4):307-313
We examined cellular membrane fatty acid composition and insulin sensitivity in patients with mild essential hypertension and hyperlipidemia, and investigated whether bezafibrate, a lipid-lowering drug, could improve elevated blood pressure and insulin sensitivity in these subjects by ameliorating cellular membrane fatty acid composition. Twenty-seven subjects were recruited. Twelve men with mild essential hypertension [systolic blood pressure (SBP) between 140 mmHg and 160 mmHg] and hypertriglyceridemia (plasma triglyceride concentration over 150 mg/dl) were designated the HL group. Fifteen men with mild essential hypertension and normotriglyceridemia (plasma triglyceride concentration below 150 mg/dl) were designated the NL group. Subjects in the HL group were given bezafibrate 400 mg/dl and those in the NL group were given placebo for 3 months. Bezafibrate significantly reduced SBP (140 +/- 2.6 to 131.8 +/- 2.6 mmHg, mean +/- SEM), diastolic blood pressure (DBP) (87.8 +/- 2.0 to 82.8 +/- 2.6 mmHg), fasting plasma triglyceride concentration (225.5 +/- 23.5 to 102.9 +/- 10.9 mg/dl), fasting plasma insulin concentration (9.6 +/- 0.8 to 7.1 +/- 0.8 microU/ml), and homeostasis model assessment scores (HOMA-R, 2.4 +/- 0.2 to 1.7 +/- 0.2), and significantly improved the insulin sensitivity index (56.0 +/- 3.0 to 70.7 +/- 4.8 mg x l2/mmol x mU x min) in the HL group. Regarding erythrocyte membrane fatty acid composition, bezafibrate reduced the percentages of saturated fatty acids (SFA) and increased the percentage of polyunsaturated fatty acids (PUFA). Plasma triglyceride concentrations were positively correlated with HOMA-R (r = 0.50, p < 0.01) and SFA (r = 0.39, p < 0.05), and negatively correlated with PUFA (r = -0.45, p < 0.05) before administration of placebo or bezafibrate. In conclusion, an improvement of hyperlipidemia by bezafibrate may be attributed to reduction of blood pressure and amelioration of insulin sensitivity. Abnormalities in membrane lipid composition may play an important role in these metabolic disorders. 相似文献
18.
Fujihiko Iwata M.D. Yoshio Hanawa M.D. Hirotada Takashima M.D. Keichou Shimoura M.D. Youhei Nishibayashi M.D. 《Pediatrics international》1992,34(1):84-86
The pathogenesis and etiology of Kawasaki disease are unknown, but some studies suggest increased genetic susceptibility. The case is presented of an infant with Kawasaki disease whose father suffered from the same illness 21 years previously. The A, B and C loci of the HLA antigens were examined. 相似文献
19.
20.
Shigeki Ohgitani Akimitsu Miyauchi Yasuyuki Takagi Yoshio Fujii Takuo Fujita Misa Nakamura Zhi-qiang Zhang Liang Shan Mitsuyo Sasaki Ryuichi Tsukino Toyoharu Yokoi Kennichi Kakudo Tomitaka Nakayama Junya Toguchida Hiroshi Kanoe Shinichi Aizawa Masao S. Sasaki Takashi Nakamura M. Suda K. Tanaka Y. Ogawa N. Tamura A. Yasoda H. Itoh M. Uehira N. Nishimoto T. Takigawa K. Shiota K. Nakao 《Journal of bone and mineral metabolism》1997,15(3):165-171